Poor
Partially Aligned
Patient Risk:
Medium
Summary
Several AI claims are not supported by the supplied label excerpts, especially adverse-effect statements framed as 'common' (dry mouth, throat irritation/cough, other anticholinergic effects) and some symptom-control/combination-use generalizations not explicitly stated in the provided label text.
Category Scores
Accurate Statements
Incruse Ellipta (umeclidinium) is an inhaled medicine used to manage chronic obstructive pulmonary disease (COPD).
Supported: Indicated for maintenance treatment of COPD (1 INDICATIONS AND USAGE; 11 DESCRIPTION).
Incruse Ellipta is a long-acting inhaled antimuscarinic (LAMA).
Supported: Long-acting muscarinic antagonist (12 CLINICAL PHARMACOLOGY 12.1).
Incruse (umeclidinium) blocks muscarinic receptors in the airways.
Supported: Inhibition of M3 receptors in airways (12.1).
Incruse Ellipta is typically taken once daily.
Supported: 1 actuation once daily; do not use more than 1 time every 24 hours (2 DOSAGE AND ADMINISTRATION).
Incruse Ellipta is administered using the Ellipta inhaler device.
Supported: Description of ELLIPTA inhaler for oral inhalation delivery (11 DESCRIPTION).
Incruse provides symptom control built over time rather than immediate relief like rescue inhalers (e.g., albuterol).
Supported: Not for acute symptoms; treat acute symptoms with short-acting beta2-agonist such as albuterol (17 PATIENT COUNSELING INFORMATION).
Patients who develop allergic-type reactions should seek medical care.
Supported: Hypersensitivity reactions may occur; discontinue and reports of anaphylaxis; severe milk protein allergy should not use (5.3).
Incruse is long-acting and is meant for ongoing symptom control.
Partially supported: Maintenance treatment and long-acting muscarinic antagonist with effects lasting longer than 24 hours; 'meant for ongoing symptom control' is consistent but not phrased verbatim (1; 12.1).
Incruse is not a quick-relief (rescue) bronchodilator used for sudden breathing trouble.
Supported: Not meant to relieve acute symptoms; extra doses should not be used for that purpose (17).
Patients with certain urinary retention problems may need extra caution with anticholinergic inhalers like Incruse.
Supported: Use with caution in patients with urinary retention; alert signs/symptoms and seek care (5.5).
Patients at risk of worsening glaucoma may need extra caution with anticholinergic inhalers like Incruse.
Supported: Use with caution in narrow-angle glaucoma; signs/symptoms and seek care (5.4).
Incruse Ellipta helps keep airways open over the day.
Partially supported: Bronchodilation with effects lasting longer than 24 hours; explicit 'keep airways open'/'over the day' wording not used (12.1; 1).
Blocking muscarinic receptors in the airways relaxes airway muscles.
Partially supported: Inhibition of M3 receptors at smooth muscle leading to bronchodilation; 'relaxes airway muscles' is an interpretive paraphrase (12.1).
Unsupported Statements
Incruse Ellipta is used to reduce symptoms of COPD such as shortness of breath.
Not supported by supplied label excerpts as symptom-by-symptom language; label states maintenance treatment without specifying shortness of breath (1 INDICATIONS AND USAGE).
Incruse can reduce airflow limitation.
No explicit 'airflow limitation' wording in the supplied excerpts; label language provided is maintenance treatment and bronchodilation (1; 12.1).
Incruse helps patients breathe more easily and consistently throughout the day.
Not supported by supplied label excerpts; provided counseling includes 'not for acute symptoms' and warnings but not this phrasing (17).
Common side effects of Incruse can include dry mouth.
Not supported by provided adverse reaction excerpts; provided sections do not list dry mouth (6 ADVERSE REACTIONS).
Common side effects of Incruse can include other anticholinergic effects.
Not supported as a 'common side effects' generalization in the provided sections; only specific interaction warning about additive anticholinergic effects is included (7.1) and specific warnings listed (5.4/5.5).
Common side effects of Incruse can include throat irritation or cough.
Not supported by provided adverse reaction excerpts; throat irritation/cough not listed in the supplied sections (6 ADVERSE REACTIONS).
In COPD treatment plans, Incruse may be used alone or combined with other long-acting medicines.
Partially supported at best; supplied label excerpt only confirms combination evaluation with ICS/LABA and does not explicitly support 'may be used alone or combined with other long-acting medicines' as stated (14 CLINICAL STUDIES; 1).
Incruse may be used in combination with other COPD medications that have different mechanisms.
Only partially supported by supplied combination-evaluation text (with ICS/LABA) and does not support the broader claim about 'different mechanisms' beyond that (14 CLINICAL STUDIES).
COPD regimens often combine inhalers with different mechanisms, for example pairing a LAMA like Incruse with a different long-acting bronchodilator.
Not supported by provided label excerpts; no label language about 'often' or specifically pairing LAMA with another long-acting bronchodilator (14 CLINICAL STUDIES).
Contradictions
Important Omissions
The label excerpt includes an explicit maximum dosing instruction ('Do not use INCRUSE ELLIPTA more than 1 time every 24 hours' and 'should be used at the same time every day') but the AI claims only 'typically taken once daily' without the 'do not exceed' and 'same time every day' phrasing.
Importance:
Moderate
Patient counseling on 'seek medical attention immediately' for specific paradoxical bronchospasm behavior is not reflected in the extracted claims (e.g., discontinue and contact provider if paradoxical bronchospasm occurs).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Medium
Adverse events were framed as 'common' (dry mouth; throat irritation/cough; other anticholinergic effects) despite not being supported by the supplied label excerpts, which could mislead patients/clinicians about expected frequency. Other statements are mostly aligned with indicated maintenance use, dosing frequency, and key caution/warning topics (glaucoma, urinary retention, hypersensitivity, not for acute symptoms).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple adverse-effect and symptom-management generalizations are not supported by the provided label excerpts and are stated as 'common,' increasing misleading counseling risk.
Suggested Improvement
Remove or rephrase unsupported adverse-effect frequency examples (e.g., dry mouth; throat irritation/cough; 'common anticholinergic effects') and avoid symptom-specific or regimen-generalization language not present in the supplied label text. Where possible, stick to label-supported elements: maintenance treatment indication, once-daily dosing constraints, not for acute symptoms, and specific caution/warning topics (narrow-angle glaucoma, urinary retention, hypersensitivity).